MedPage Today -- Prophylactic nadroparin (Fraxiparine), a low-molecular-weight heparin, significantly reduced the risk of thromboembolism in cancer patients receiving outpatient chemotherapy, a randomized trial showed.
MedPage Today -- Prophylactic nadroparin (Fraxiparine), a low-molecular-weight heparin, significantly reduced the risk of thromboembolism in cancer patients receiving outpatient chemotherapy, a randomized trial showed.